COMMUNIQUÉS West-GlobeNewswire

Novartis announces offer to acquire CellforCure to expand manufacturing capacity for innovative cell and gene therapies
20/12/2018
Proposed acquisition builds on existing agreement with CellforCure for contract manufacturing of Novartis leading CAR-T cell therapy Kymriah ® (tisagenlecleucel) and recent successful completion of technology transfer [...]
RUDDCO Inc. Announces the Start of Operations in the Cranbrook Botanical Garden
20/12/2018
MIAMI, Dec. 20, 2018 (GLOBE NEWSWIRE) -- Ruddco Inc., a Florida-based company, in conjunction with Orange Hill Limited under a joint venture agreement is announcing an expansion of cannabis operations and the opening of [...]
Endocyte Stockholders Approve Merger Agreement with Novartis AG
20/12/2018
WEST LAFAYETTE, Ind., Dec. 20, 2018 (GLOBE NEWSWIRE) -- Endocyte, Inc. (Nasdaq:ECYT) (“Endocyte”), a biopharmaceutical company developing targeted therapeutics for cancer treatment, today announced that at its Special [...]
The Financial Calendar of JSC “Grindeks” for the year of 2019
20/12/2018
JSC "Grindeks" plans to publish its: non-audited interim financial statement for the 12-month period of 2018 on 28 February 2019; non-audited interim financial statement for the 3-month period of 2019 on 30 May 2019; [...]
Assertio Therapeutics Announces Submission of NDA for FDA Approval of Cosyntropin Depot
20/12/2018
-- Submission Advances Company’s Strategy to Build A New Orphan/Specialty Business and Aligns with Company’s Mission of Putting Patients First -- LAKE FOREST, Ill., Dec. 20, 2018 (GLOBE NEWSWIRE) -- Assertio [...]
WATS3D Markedly Improves Detection of Esophageal Dysplasia and Barrett’s Esophagus in 12,899 Patient Study in the “Real World” Practice setting of 58 Community-Based Gastroenterologists
20/12/2018
- New Study with Largest Data Set to Date Demonstrates that Adjunctive Use of WATS 3D Significantly Increases Detection of Esophageal Precancer - - Study Published in Diseases of the Esophagus - SUFFERN, N.Y., Dec. 20, [...]
CV Sciences, Inc. to Present at Biotech Showcase™ Investor Conference on January 7th in San Francisco
20/12/2018
The Company’s executive team to meet with investors at one of industry’s largest annual healthcare conferences LAS VEGAS, Dec. 20, 2018 (GLOBE NEWSWIRE) -- CV Sciences, Inc. (OTCQB: CVSI) preeminent supplier and [...]
Matinas BioPharma to Present at Biotech Showcase 2019
20/12/2018
– Presentation with live audio webcast Monday, January 7th at 3:30 PM PST – BEDMINSTER, N.J., Dec. 20, 2018 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), a clinical-stage biopharmaceutical [...]
Mustang Bio Receives Orphan Drug Designation for MB-102 (CD123 CAR T) for the Treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm
20/12/2018
NEW YORK, Dec. 20, 2018 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a company focused on the development of novel immunotherapies based on proprietary chimeric antigen receptor engineered T cell ( [...]
Galectin Therapeutics Announces Extension of $10 Million Line Credit
20/12/2018
NORCROSS, Ga., Dec. 20, 2018 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today announced that its $10 million unsecured line of [...]
Assure Holdings Appoints Dr. Christopher Rumana to its Board of Directors
20/12/2018
DENVER, Dec. 20, 2018 (GLOBE NEWSWIRE) -- Assure Holdings Corp. (the “ Company ” or “ Assure ”) (TSXV: IOM; OTCPK: ARHH), a provider of intraoperative neuromonitoring services, has appointed Dr. Christopher Rumana to [...]
Adverum to Present at the 37th Annual J.P. Morgan Healthcare Conference
20/12/2018
MENLO PARK, Calif., Dec. 20, 2018 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ophthalmology and rare diseases, today announced [...]
Sarepta Therapeutics Completes Submission of New Drug Application Seeking Approval of Golodirsen (SRP-4053) in Patients with Duchenne Muscular Dystrophy Amenable to Skipping Exon 53
20/12/2018
-- Golodirsen has been studied for the treatment of exon 53 amenable patients, approximately eight percent of patients with Duchenne -- -- Submission represents ongoing advancement of the company’s proprietary PMO RNA- [...]
Director/PDMR Shareholding
20/12/2018
Director/PDMR Shareholding 20 December, 2018 – Shire plc (LSE: SHP, NASDAQ: SHPG) Notification of transactions by persons discharging managerial responsibilities 1. Details of the person discharging managerial [...]
Acasti Pharma Achieves Planned Enrollment Targets for TRILOGY Phase 3 Trials of CaPre® in Patients with Severe Hypertriglyceridemia
20/12/2018
LAVAL, Québec, Dec. 20, 2018 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (“Acasti or the “Company”) (NASDAQ: ACST – TSX-V: ACST), a biopharmaceutical innovator focused on the research, development and commercialization of [...]
Synthorx Appoints Andrew Powell, J.D., to its Board of Directors
20/12/2018
Pratik Shah., Ph.D., Appointed Chairman of the Board SAN DIEGO, Dec. 20, 2018 (GLOBE NEWSWIRE) -- Synthorx, Inc. (NASDAQ: THOR), a biotechnology company using a first-of-its-kind Expanded Genetic Alphabet platform [...]
NORTHBUD Amends Licence Application to Add 500K SQ. FT. of Outdoor Cultivation Area and Provides a Corporate Update
20/12/2018
TORONTO, Dec. 20, 2018 (GLOBE NEWSWIRE) -- North Bud Farms Inc. (CSE: NBUD) ("NORTHBUD" or the "Company") announced the amendment of its licence application to add 500K SQ. FT. of outdoor cultivation area and provides [...]
VBI Vaccines Announces Phase 2 Clinical Study Design of its Prophylactic CMV Vaccine Candidate
20/12/2018
CAMBRIDGE, Mass., Dec. 20, 2018 (GLOBE NEWSWIRE) -- VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a commercial-stage biopharmaceutical company developing next-generation infectious disease and immuno-oncology vaccines, today [...]
CytomX Therapeutics Announces Changes to its Board of Directors
20/12/2018
- President and CEO Sean McCarthy, D. Phil., Appointed to Additional Role of Chairman - - Hoyoung Huh, M.D., Ph.D. Retiring from Board - - James R. Meyers, Former EVP at Gilead Sciences, Appointed to Board - SOUTH SAN [...]

Pages